when were glp-1 agonists approved for weight loss Glucagon-like peptide-1 receptor: mechanisms and advances in therapy Navigating the -tides: Medication-Assisted Weight

These processes collectively suppress reactive oxygen species (ROS) production, thereby attenuating the proinflammatory cascade that would otherwise lead to increased nuclear factor kappa-light-chain-enhancer of activated -cells (NF-kB) expression and cytokine release

doi: 10.1038/IJO.2009.184

HFrEF, heart failure with reduced ejection fraction

Evaluation of the Incretin Effect in Humans Using GIP and GLP-1 Receptor Antagonists

"As clinicians, recognizing that people can get double benefits from something is always helpful and as more obesity medications enter the market, this can help personalize treatments," she said

Future research must address these gaps, focusing on long-term safety, optimizing combination approaches, and evaluating the broader clinical and economic implications of widespread GLP-1 RA use